Expression of nectin-4 in papillary renal cell carcinoma

Zschabitz S, Mikuteit M, Stoehr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Stroebel P, Becker F, Wuelfing C, Barth P, Stoeckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Goeppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 13

Article Number: 90

Journal Issue: 1

DOI: 10.1007/s12672-022-00558-2

Abstract

Background: Nectin-4 contributes to tumor proliferation, lymphangiogenesis and angiogenesis in malignant tumors and is an emerging target in tumor therapy. In renal cell carcinoma (RCC) VEGF-directed tyrosine kinase inhibitors and checkpoint inhibitors are currently treatments of choice. Enfortumab vedotin-ejf (EV) is an antibody drug conjugate that targets Nectin-4. The aim of our study was to investigate the expression of Nectin-4 in a large cohort of papillary RCC specimens. Patients and methods: Specimens were derived from the PANZAR consortium (Erlangen, Heidelberg, Herne, Homburg, Mainz, Mannheim, Marburg, Muenster, LMU Munich, TU Munich, and Regensburg). Clinical data and tissue samples from n = 190 and n = 107 patients with type 1 and 2 pRCC, respectively, were available. Expression of Nectin-4 was determined by immunohistochemistry (IHC). Results: In total, Nectin-4 staining was moderately or strongly positive in of 92 (48.4%) of type 1 and 39 (36.4%) type 2 of pRCC cases. No associations between Nectin-4 expression and age at diagnosis, gender, grading, and TNM stage was found. 5 year overall survival rate was not statistically different in patients with Nectin-4 negative versus Nectin-4 positive tumors for the overall cohort and the pRCC type 2 subgroup, but higher in patient with Nectin-4 positive pRCC type 1 tumors compared to Nectin-4 negative tumors (81.3% vs. 67.8%, p = 0.042). Conclusion: Nectin-4 could not be confirmed as a prognostic marker in pRCC in general. Due to its high abundance on pRCC specimens Nectin-4 is an interesting target for therapeutical approaches e.g. with EV. Clinical trials are warranted to elucidate its role in the pRCC treatment landscape.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Münster Germany (DE) Universitätsklinikum Göttingen Germany (DE) Universitätsklinikum des Saarlandes (UKS) Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Caritas-Krankenhaus St. Josef Regensburg Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Ruhr-Universität Bochum (RUB) Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Philipps-Universität Marburg Germany (DE)

How to cite

APA:

Zschabitz, S., Mikuteit, M., Stoehr, C., Herrmann, E., Polifka, I., Agaimy, A.,... Steffens, S. (2022). Expression of nectin-4 in papillary renal cell carcinoma. Discover Oncology, 13(1). https://doi.org/10.1007/s12672-022-00558-2

MLA:

Zschabitz, Stefanie, et al. "Expression of nectin-4 in papillary renal cell carcinoma." Discover Oncology 13.1 (2022).

BibTeX: Download